Cerner Leverages Real-World Evidence to Advance Therapies

Cerner recently launched a new operating unit, Cerner Enviza, that offers data-driven solutions and research services to clarify multi-dimensional data through real-world evidence and insights. 

New therapies generally take an average of 17 years and $2.5 billion to reach patients. 

Cerner created Cerner Enviza to unlock the power of data and a network of health systems to get therapies to patients more quickly at a lower cost. The unit will also broaden the availability and participation in clinical trials to help achieve more equitable results. 

Overall, by combining life sciences knowledge and collaborative research, Cerner Enviza provides data-driven solutions and expertise to help bring clarity to healthcare’s most important decisions.

“The true promise of the digital age is to use data to improve everyday health around the world,” David Feinberg, MD, president and CEO of Cerner, said in the announcement. 

“We have to break down industry silos and evolve from simply accumulating data to generating meaningful insights that can accelerate therapy development. With Cerner Enviza, we can arm researchers with diverse tools and datasets to help them address these challenges and help change the way we develop and deliver care for our patients,” Feinberg continued. 

For over 20 years, Cerner has offered research and real-world data solutions to help caregivers and investigators advance their efforts. 

In April 2021, Cerner acquired Kantar for $375 million to accelerate innovation in life sciences research and improve patient outcomes globally. Over the years, Kantar has helped life science researchers leverage data to better understand patient and treatment journeys. 

Under the recent initiative, Cerner and Kantar will combine their expertise to help boost discovery, development, and deployment of therapies and advance research and the life sciences industry to improve everyday health. 

“With Cerner Enviza, we bring together the expertise, assets and capabilities of Kantar Health with Cerner’s technology and access to a large collection of deidentified patient health data,” said Mike Kelly, global head of Cerner Enviza. 

“Our approach unites the life sciences and healthcare providers to support research and trial opportunities across this ecosystem,” Kelly concluded.